CR8942A - CONJUGATES OF HUMAN GROWTH HORMONE AND POLYETHYLENE GLYCOL RAMIFIED WITH GLICEROL, PROCESS FOR PREPARATION AND METHODS OF USE OF THE SAME - Google Patents

CONJUGATES OF HUMAN GROWTH HORMONE AND POLYETHYLENE GLYCOL RAMIFIED WITH GLICEROL, PROCESS FOR PREPARATION AND METHODS OF USE OF THE SAME

Info

Publication number
CR8942A
CR8942A CR8942A CR8942A CR8942A CR 8942 A CR8942 A CR 8942A CR 8942 A CR8942 A CR 8942A CR 8942 A CR8942 A CR 8942A CR 8942 A CR8942 A CR 8942A
Authority
CR
Costa Rica
Prior art keywords
growth hormone
human growth
glicerol
ramified
conjugates
Prior art date
Application number
CR8942A
Other languages
Spanish (es)
Inventor
F Finn Rory
R Siegel Ned
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8942(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of CR8942A publication Critical patent/CR8942A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a la PEGilacion de la hormona del crecimiento humana (hGH) usando un PEG ramificado con glicerol. La presente invencion tambien se refiere a procesos para la PEGilacion de hGH. Ademas, la presente invencion se refiere a composiciones farmaceuticas que comprenden la hGH PEGilada. Otra realizacion es el uso de la hGH PEGilada para el tratamiento de trastornos del crecimiento y del desarrollo.The present invention relates to the PEGylation of human growth hormone (hGH) using a PEG branched with glycerol. The present invention also relates to processes for the PEGylation of hGH. In addition, the present invention relates to pharmaceutical compositions comprising PEGylated hGH. Another embodiment is the use of PEGylated hGH for the treatment of growth and development disorders.

CR8942A 2004-08-31 2007-02-26 CONJUGATES OF HUMAN GROWTH HORMONE AND POLYETHYLENE GLYCOL RAMIFIED WITH GLICEROL, PROCESS FOR PREPARATION AND METHODS OF USE OF THE SAME CR8942A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60594504P 2004-08-31 2004-08-31

Publications (1)

Publication Number Publication Date
CR8942A true CR8942A (en) 2007-08-16

Family

ID=35708806

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8942A CR8942A (en) 2004-08-31 2007-02-26 CONJUGATES OF HUMAN GROWTH HORMONE AND POLYETHYLENE GLYCOL RAMIFIED WITH GLICEROL, PROCESS FOR PREPARATION AND METHODS OF USE OF THE SAME

Country Status (24)

Country Link
EP (1) EP1789092A2 (en)
JP (1) JP2008511610A (en)
KR (1) KR20070042567A (en)
CN (1) CN101010105A (en)
AP (1) AP2007003919A0 (en)
AR (1) AR050851A1 (en)
AU (1) AU2005278903A1 (en)
BR (1) BRPI0515118A (en)
CA (1) CA2577999A1 (en)
CR (1) CR8942A (en)
EA (1) EA200700380A1 (en)
EC (1) ECSP077281A (en)
GT (1) GT200500235A (en)
IL (1) IL181085A0 (en)
MA (1) MA28908B1 (en)
MX (1) MX2007002441A (en)
NL (1) NL1029828C2 (en)
NO (1) NO20071322L (en)
PE (1) PE20060654A1 (en)
TN (1) TNSN07078A1 (en)
TW (1) TW200621291A (en)
UY (1) UY29088A1 (en)
WO (1) WO2006024953A2 (en)
ZA (1) ZA200701802B (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
ATE375363T1 (en) 1997-07-14 2007-10-15 Bolder Biotechnology Inc GROWTH HORMONE DERIVATIVES AND RELATED PROTEINS
AU775937B2 (en) 1999-01-14 2004-08-19 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
JP2009536963A (en) * 2006-05-12 2009-10-22 ドン・ア・ファーム・カンパニー・リミテッド Polyethylene glycol-interferon α conjugate
JP2008069073A (en) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd Lactoferrin conjugate and its manufacturing method
KR101079993B1 (en) * 2006-11-17 2011-11-04 동아제약주식회사 Polyethylene glycol-G-CSF conjugate
CL2008002399A1 (en) 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
EP2300501B1 (en) * 2008-07-23 2014-08-20 Hanmi Science Co., Ltd. A polypeptide complex comprising non-peptidyl polymer having three functional ends
JP5639585B2 (en) 2008-07-31 2014-12-10 ファーマエッセンティア コーポレイション Peptide-polymer conjugate
US8535655B2 (en) 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
SI2340271T1 (en) * 2008-10-10 2019-08-30 Polyactiva Pty Ltd. Polymer-bioactive agent conjugates
WO2010040188A1 (en) * 2008-10-10 2010-04-15 The Bionic Ear Institute Biodegradable polymer - bioactive moiety conjugates
DK3178835T3 (en) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc EXTENDED RECOMBINANT POLYPEPTIDES AND COMPOSITIONS INCLUDING THE SAME
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
CN101831067A (en) * 2010-05-31 2010-09-15 王二新 Polyethylene glycol ester conjugate and application thereof in medicine preparation
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
CN102367290B (en) * 2011-04-26 2013-05-08 厦门赛诺邦格生物科技有限公司 Chain-functionalized multi-level branched polyethylene glycol and synthesis method thereof
CN104302408B (en) * 2012-02-27 2016-12-14 阿穆尼克斯运营公司 XTEN conjugate compositions and methods of making same
EP2947111B1 (en) * 2013-01-17 2018-03-07 Xiamen Sinopeg Biotech Co., Ltd. Monofunctional branched polyethyleneglycol and bio-related substance modified by same
CN104877127B (en) * 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 A kind of eight arms polyethyleneglycol derivative, preparation method and its bio-related substance of modification
AU2015342908B2 (en) 2014-11-06 2021-06-24 Pharmaessentia Corporation Dosage regimen for pegylated interferon
US12208142B2 (en) 2017-12-29 2025-01-28 Hoffmann-La Roche Inc. Process for providing PEGylated protein composition
CN111801120A (en) 2017-12-29 2020-10-20 豪夫迈·罗氏有限公司 Methods for providing PEGylated protein compositions
PL3731873T3 (en) * 2017-12-29 2022-04-25 F. Hoffmann-La Roche Ag Process for providing pegylated protein composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
JP3092531B2 (en) * 1996-11-05 2000-09-25 日本油脂株式会社 Method for producing imidyl succinate-substituted polyoxyalkylene derivative
ATE375363T1 (en) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc GROWTH HORMONE DERIVATIVES AND RELATED PROTEINS
JP3921781B2 (en) * 1998-02-12 2007-05-30 日本油脂株式会社 Carboxyl group-containing polyoxyalkylene compound
AU775937B2 (en) * 1999-01-14 2004-08-19 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
OA13063A (en) * 2001-11-20 2006-11-10 Pharmacia Corp Chemically-modified human growth hormone conjugates.
JP4764630B2 (en) * 2002-09-09 2011-09-07 ネクター セラピューティックス Water-soluble polymer alkanal
JP4412461B2 (en) * 2002-11-20 2010-02-10 日油株式会社 Modified bio-related substance, production method thereof and intermediate
US7208145B2 (en) * 2002-12-31 2007-04-24 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a ketone or a related functional group
PT2644206T (en) * 2003-05-23 2019-07-10 Nektar Therapeutics Peg derivatives containing two peg chains

Also Published As

Publication number Publication date
NL1029828A1 (en) 2006-03-01
BRPI0515118A (en) 2008-07-01
TNSN07078A1 (en) 2008-06-02
MA28908B1 (en) 2007-10-01
WO2006024953A3 (en) 2007-01-18
UY29088A1 (en) 2006-03-31
CN101010105A (en) 2007-08-01
KR20070042567A (en) 2007-04-23
ZA200701802B (en) 2008-08-27
PE20060654A1 (en) 2006-08-12
EA200700380A1 (en) 2007-10-26
AP2007003919A0 (en) 2007-02-28
CA2577999A1 (en) 2006-03-09
AU2005278903A1 (en) 2006-03-09
JP2008511610A (en) 2008-04-17
AR050851A1 (en) 2006-11-29
NO20071322L (en) 2007-05-29
MX2007002441A (en) 2007-05-04
EP1789092A2 (en) 2007-05-30
TW200621291A (en) 2006-07-01
GT200500235A (en) 2006-03-21
ECSP077281A (en) 2007-03-29
WO2006024953A2 (en) 2006-03-09
IL181085A0 (en) 2007-07-04
NL1029828C2 (en) 2006-10-20

Similar Documents

Publication Publication Date Title
ECSP077281A (en) CONJUGATES OF HUMAN GROWTH HORMONE AND POLYETHYLENE GLYCOL RAMIFIED WITH GLICEROL, PROCESS FOR PREPARATION AND METHODS OF USE OF THE SAME
BRPI0513508A (en) insulin-oligomer conjugates, formulations and uses of these
BR0313343A (en) Use of a mixture of permeation agents, nail and periungual solutions and use of a nail and periungual solution
NZ591261A (en) Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
CO6501124A2 (en) IMMUNOMODULATING POLYPEPTIDES DERIVED IS THE IL 2 AND ITS THERAPEUTIC USE IN CANCER AND IN CHRONIC INFECTIONS
AR069903A1 (en) ANTIBODY CONJUGATE - ASSOCIATED MOLECULA DIRECTED TO THE PROTEIN TIROSINA QUINASA 7 (PTK 7), PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, NUCLEIC ACID, EXPRESSION FACTOR AND RELATED HUMAN CELL AND ITS USE TO PREPARE A MEDICATION
CR11648A (en) COMPOSITION UNDERSTANDING ANTIBODY THAT IS SET TO DOMAIN II OF HER2, AND ITS VARIOUS ACIDS
DK2249869T3 (en) Liquid formulation of FSH
CY1111177T1 (en) FAINOTHEASINE UNION FOR INJURY HEALING
BRPI0409133B8 (en) stable pharmaceutical preparations comprising methylnaltrexone
UA91575C2 (en) Four branched dendrimer-peg for conjugation to proteins and peptides
AR069830A1 (en) FACTOR VIII AND FACTOR OF VON WILLEBRAND MODIFIED RECOMBINANTS AND METHODS OF USE OF THE SAME
IT1288290B1 (en) SELF-LETICULATED HYALURONIC ACID AND RELATED PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ARTHROPATHIES
CR8722A (en) METADONA COMPOSITIONS FOR TOPICAL USE AND METHODS FOR THE USE OF THE SAME
NI201000193A (en) ORAL FORMULATIONS OF CITIDINE ANALOGUES AND METHODS OF USE OF THE SAME.
EA200701065A1 (en) INJECTABLE COMPOSITIONS CONTAINING NANODISPERS Olanzapine
PA8594801A1 (en) PALANOSETRON LIQUID PHARMACEUTICAL FORMULATIONS
CL2012000261A1 (en) Liquid pharmaceutical composition of 4- {[9-chloro-7- (2-fluoro-6-methoxyphenyl) -5h-pyrimido [5,4-d] [2] benzazepin-2-yl] amino} -2-methoxybenzoic acid in a mixed solvent with at least 15% propylene glycol, 15% peg400 and less than 50% water; and its use for the preparation of a medicament for the treatment of cancer.
BRPI0510654A (en) interferon hydrogel formulations
CL2012003038A1 (en) Polyethylene glycol conjugate to factor viia; pharmaceutical composition comprising said polyethylene glycol conjugated to factor viia; use of a pharmaceutical composition to treat disease or trauma of blood clotting in a patient in need; process to prepare the following polyethylene glycol conjugate to viia factor.
WO2007059979A3 (en) Allergy treatment by epicutaneous allergen administration
MX2012007225A (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue.
CR11406A (en) NEURTURINE CONJUGATES NEW FOR PHARMACEUTICAL USE
AR077347A1 (en) IMPROVEMENTS IN PHARMACEUTICAL COMPOSITIONS AND RELATED TO THEM
BRPI0606396A2 (en) tripeptide and tetrapeptide sulfones, pharmaceutical composition containing them, related use and method of preparation of said sulfones

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)